The European Commission has approved ThromboGenics' Jetrea (ocriplasmin) for the treatment of vitreomacular traction (VMT), including when coupled with macular hole of diameter less than or equal to 400 microns, in the European Union (EU). ...
Tags: ThromboGenics Jetrea, vitreomacular traction treatment, drug